Tvardi Therapeutics, Inc.
TVRD
$26.22
$0.170.65%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
6/5/2025
-
Tickeron - Stocks
6/2/2025
-
TipRanks Financial Blog
5/30/2025
-
GuruFocus
5/30/2025
-
TipRanks Financial Blog
5/30/2025
-
SeekingAlpha.com: All News
5/30/2025
-
The Fly
5/27/2025
-
GuruFocus
5/27/2025
-
GuruFocus
5/27/2025
-
GuruFocus
5/27/2025
-
TipRanks Financial Blog
5/27/2025
-
TipRanks Financial Blog
5/27/2025
-
The Fly
5/27/2025
-
Business Wire
5/24/2025
-
Tickeron - Stocks
5/24/2025
-
Tickeron - Stocks
5/23/2025
-
Tickeron - Stocks
5/21/2025
-
GuruFocus
5/21/2025
-
Tickeron - Technical Analysis
5/21/2025
-
GuruFocus
5/21/2025
-
The Fly
5/20/2025
-
GuruFocus
5/20/2025
-
GuruFocus
5/20/2025
-
Business Wire
5/17/2025
-
Tickeron - Technical Analysis
5/17/2025
-
Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Tuesday, May 13, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
713 489 8654
Address
3 Sugar Creek Center Boulevard
Sugar Land, TX 77478
Sugar Land, TX 77478
Country
Year Founded
--
Business Description
Sector
Tvardi Therapeutics, Inc. operates as a biotechnology company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. The...
more